HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme
Help Login Register
Market News Stocks News ETF News Crypto News

Eupraxia Pharmaceuticals Inc.

Contributing Author

Recent Articles by Eupraxia Pharmaceuticals Inc.

8 hours
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis EPRX GlobeNewswire
Jun-02
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders EPRX GlobeNewswire
May-07
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 EPRX GlobeNewswire
May-06
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results EPRX GlobeNewswire
May-05
Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI EPRX GlobeNewswire
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite